Anna Berry

Dr. Anna Berry is the Senior Vice President, Biomarker Data and Laboratory Medicine at Syapse, where she works in partnership with Syapse’s functional leaders to support product and service development, serves as a subject matter expert to Syapse’s customers, participates in joint-authored research and publications, and advances Syapse’s thought leadership efforts in the area of real-world evidence. Prior to her recent move to Syapse, she served for 6 years as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle, and concurrently served as Director of Genomics Programs at CellNetix Pathology and Laboratories. She has also served on the faculty at the University of California San Francisco for 9 years, where she rose to the rank of Associate Professor. While at UCSF, she was the inaugural Director of Molecular Pathology, and the inaugural Molecular Genetic Pathology Fellowship Director, and served as an attending physician in the Fine Needle Aspiration Clinic. Dr. Berry has focused professionally on genomics education and personalized medicine. In these roles, she has given numerous presentations, nationally and internationally, and has served on multiple task forces and committees for several professional organizations and coalitions, spanning Pathology and Oncology focused efforts. She has also been published in these areas of study. Dr. Berry completed her undergraduate studies at the University of Wyoming and earned her medical degree from the University of Nebraska Medical Center. She has board certifications in Anatomic and Clinical Pathology, Cytopathology, and Molecular Genetic Pathology.